ID   RT4/31
AC   CVCL_2715
DR   cancercelllines; CVCL_2715
DR   ECACC; 86082102
DR   Wikidata; Q54951364
RX   PubMed=29732388;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3690; FGFR3 + HGNC; HGNC:11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:12362; TSC1; Simple; p.Leu557Cysfs*72 (c.1669delC); ClinVar=VCV000048811; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0036 ! RT-4
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 17
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon, Tahlita C.M.
RA   de Jong, Florus Christiaan
RA   Costello, James C.
RA   Theodorescu, Dan
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//